Carbohydrate-protein (CHO+Pro) beverages reportedly improve endurance and indices of muscle disruption, but it is unclear whether these effects are related to total energy intake or specific effects of protein. Purpose: The authors examined effects of CHO+Pro on time to exhaustion and markers of muscle disruption compared with placebo (PLA) and carbohydrate beverages matched for carbohydrate (CHO) and total calories (CHO+CHO). Methods: Eleven male cyclists completed 4 rides to exhaustion at 75% VO 2peak . Participants consumed 250 ml of PLA, CHO (7.75%), CHO+CHO (9.69%), or CHO+Pro (7.75%/1.94%) every 15 min until fatigue, in a double-blind design. Results: Time to exhaustion was significantly longer (p < .05) in CHO+Pro (126.2 ± 25.4 min) and CHO+CHO (121.3 ± 36.8) than PLA (107.1 ± 30.3). CHO (117.5 ± 24.2) and PLA were not significantly different. Similarly, CHO+Pro was not significantly different from CHO and CHO+CHO. Postexercise plasma creatine kinase was lower after CHO+Pro (197.2 ± 149.2 IU/L) than PLA (407.4 ± 391.3), CHO (373.2 ± 416.6), and CHO+CHO (412.3 ± 410.2). Postexercise serum myoglobin was lower in CHO+Pro (47.0 ± 27.4 ng/mL) than all other treatments (168.8 ± 217.3, 82.6 ± 71.3, and 72.0 ± 75.8). Postexercise leg extensions at 70% 1RM were significantly greater 24 hr after CHO+Pro (11.3 ± 4.1) than PLA (8.8 ± 3.7), CHO (9.7 ± 4.3), and CHO+CHO (9.5 ± 3.6). Conclusion: These findings suggest that at least some of the reported improvements in endurance with CHO+Pro beverages might be related to caloric differences between treatments. Postexercise improvements in markers of muscle disruption with CHO+Pro ingestion appear to be independent of carbohydrate and caloric content and were elicited with beverages consumed only during exercise.
not total caloric content, suggesting that adding protein to a typical carbohydrate sports drink (6-8% CHO) can improve endurance. A recent study from Romano-Ely, Todd, Saunders, and St. Laurent (2006) , however, reported no differences in time to exhaustion between isocaloric CHO+Pro and CHO beverages. This suggests that a primary factor for the benefits of CHO+Pro is the additional availability of calories in CHO+Pro beverages. These findings could alternatively support a protein-mediated benefit of CHO+Pro ingestion, because performance in the CHO+Pro trial equaled that in the CHO trial, despite 20% lower carbohydrate content in the CHO+Pro beverage. Previous studies reporting ergogenic effects of CHO+Pro compared beverages delivered at rates of 37-47 g CHO/hr Saunders et al., 2004 Saunders et al., , 2007 , below the maximal oxidation rates of exogenous carbohydrate. Thus, it is unclear whether adding protein to a beverage containing carbohydrate provided at peak exogenous oxidation rates (60-90 g CHO/hr; Jentjens, Moseley, Waring, Harding, Jentjens, Venables, & Jeukendrup, 2004; Jeukendrup & Jentjens, 2000) will elicit further improvements in performance.
Consumption of CHO+Pro beverages has been associated with reductions in markers of sarcolemmal disruption, such as plasma creatine kinase (CK; Luden, Saunders, & Todd, 2007; Romano-Ely et al., 2006; Saunders et al., 2004 Saunders et al., , 2007 and lactate dehydrogenase (Romano-Ely et al.) , and muscle soreness Romano-Ely et al., 2006 ) when compared with CHO beverages matched for carbohydrate content Saunders et al., 2004 Saunders et al., , 2007 or total calories (Romano-Ely et al.) . Beverages in these studies were provided both during and immediately after exercise, however, so it is unclear whether feedings provided only during exercise would elicit these effects. In addition, the investigations cited did not assess muscle function, so it is difficult to determine whether the reported changes in sarcolemmal disruption and soreness with CHO+Pro ingestion are functionally relevant to athletes.
The purpose of the current study was to examine the effects of a CHO+Pro beverage provided only during exercise on time to exhaustion and markers of muscle disruption after exercise. Specifically, the following questions were addressed: (a) Does a CHO+Pro beverage improve time to exhaustion compared with placebo or CHO beverages, when treatments equal or exceed maximal exogenous CHO oxidation levels, and (b) does a CHO+Pro beverage provided during exercise attenuate plasma CK, serum myoglobin (Mb), and muscle soreness and improve muscle function compared with placebo or CHO beverages?
Methods

Participants
Twelve men between 18 and 26 years of age participated in this study. All participants performed at least 4 days of aerobic training per week, including at least 2 days of bicycle training, and demonstrated a VO 2peak above 45 ml · kg -1 · min -1 . Additional demographic information is provided in Table 1 .
Participants completed an informed consent and comprehensive health-status questionnaire to determine whether they had any health conditions precluding safe participation in the study and were excluded if deemed at risk for cardiovascular disease according to ACSM guidelines (American College of Sports Medicine, 2006) . The institutional review board of James Madison University granted approval of the experimental design and all procedures.
Phase 1
On completion of the initial screening, all qualified participants completed a physical fitness and strength assessment to determine the exercise intensities to be implemented during Phases 2-5 of the study. Height, body mass, and body-fat percentage were also measured for demographic purposes, as described herein.
Body mass and height were determined using a physician's scale with stadiometer and were recorded to the nearest 0.1 kg and 0.5 cm, respectively. Participants were measured in their cycling shorts only, without shoes, socks, or shirt. Body-fat percentage was assessed using a three-site skinfold technique consisting of abdomen, pectoral, and thigh locations (Jackson & Pollock, 1985) .
Participants performed a graded exercise test on an electronically braked cycle ergometer (Ergoline 800S, SensorMedics, Yorba Linda, CA) to determine peak oxygen uptake (VO 2peak ) as previously described (Saunders et al., 2004) . Metabolic measurements including VO 2 , VCO 2 , and respiratory-exchange ratio (RER) were obtained continuously during this test using a SensorMedics Vmax Spectra metabolic cart (Yorba Linda, CA). Heart rate (HR) and ratings of perceived exertion (RPE) were obtained near completion of each 60-s period during the graded exercise test via a Polar heart-rate monitor (Brooklyn, NY) and Borg's 6-to 20-point scale (Borg, 1982) .
Participants performed a one-repetition-maximum (1RM) leg extension with their dominant leg on a Cybex leg-extension machine (Cybex International, Inc., Medway, MA). The machine was adjusted to ensure that movement was initiated at a joint angle of approximately 90°. This setting was recorded for each participant and duplicated in all subsequent testing, to ensure consistent testing for each individual. Participants performed the leg extension with arms folded across their chest to prevent them from using their arms for leverage. After a self-selected warm-up, participants attempted ~60% of body weight, and resistance was progressively increased until a 1RM was achieved (approximately four trials). This single-leg strength assessment was used to determine the appropriate resistance for the muscle-function testing during Phases 2-5. 
Phase 2
Participants performed a prolonged bout of cycle ergometry to exhaustion in thermoneutral conditions (20-22 °C). The intensity for each experimental ride was set at 75% VO 2peak , and participants rode at a self-selected cadence of >50 rpm. Time to exhaustion was recorded at the time point when participants were unable to maintain this minimum cadence for 20 s. Participants received 250 ml of treatment beverage every 15 min for the duration of the ride. Figure 1 provides an overview of measurement procedures during the experimental ride. In addition to recording time to exhaustion, the following measurements were obtained during and after the performance rides: VO 2 , VCO 2 , and RER were recorded at 30-min intervals throughout the ride. HR and RPE were obtained at the same time points, using the methods described previously. Blood samples were obtained from an antecubital vein immediately before each experimental ride and 22-24 hr after exercise to assess plasma CK levels. Samples were collected in lithium heparin Vacutainer tubes while participants were in a seated position with their elbow resting on a desktop. Whole blood was centrifuged at 7,000 rpm for 10 min. Plasma was removed and stored without additive at -60 °C for later analysis. Frozen plasma samples were brought to room temperature (22 °C) and mixed through gentle inversion. Plasma CK was then analyzed using a Johnson & Johnson Vitro DT 6011. The measurement device was calibrated before analyses using a reconstituted lyophilized calibration standard purchased from the manufacturer. In addition, CK controls were analyzed at room temperature using CK standards containing low (112-176 U/L) and high (843-1,095 U/L) concentrations of CK, to confirm an accurate calibration. Specific timing of postexercise blood collection remained consistent for each participant. Time points for plasma CK measurements were selected for consistency with previous studies Romano-Ely et al., 2006) and to capture postexercise CK values when they were presumed to approximate maximal levels (Henry, 2001) . To ensure that CK values were not affected by potential plasma-volume shifts, data were adjusted for changes in plasma volume using equations from Dill and Costill (1974) . To do so, hemoglobin and hematocrit levels were also obtained at these time points. Hemoglobin was measured spectrophotometrically (Genesys 6 Thermospectronic) at a wavelength of 660 nm and compared with standards according to manufacturers' instructions. Hematocrit was assessed by centrifuging whole blood in capillary tubes and measuring the proportion of packed cells to total blood volume. Blood samples were obtained before each experimental ride and 6-9 hr after exercise to assess serum Mb levels. Samples were collected in SST clot agent Vacutainer tubes and centrifuged, and serum was removed and stored as described previously. Myoglobin levels were measured from serum using commercially available ELISA kits (BioCheck, Inc.) according to the manufacturers' instructions. A standard curve was prepared using reference standards ranging from 0 to 1,000 ng/mL Mb. Absorbance of the 96-well assay plate was read at a wavelength of 450 nm using a microplate spectrophotometer. All samples were run in duplicate on the same assay plate. Timing of postexercise blood collection was selected to capture postexercise Mb values when they were presumed to approximate maximal levels (Henry, 2001; Norregaard-Hansen et al., 1986) . As described previously, Mb values were adjusted for potential changes in plasma volume using equations from Dill and Costill (1974) .
Whole blood was obtained before exercise and at 30-min intervals during exercise through the use of finger sticks to the tip of the finger, acquiring ~0.2 ml of blood at each sampling. Glucose and lactate concentrations were determined immediately from whole blood using an automated glucose/lactate analyzer (YSI 2300 STAT Plus), which was calibrated before each trial.
Whole blood was obtained immediately before each experimental ride and immediately after exercise to assess serum insulin levels. Postexercise blood samples were obtained within 1-2 min postexercise, with the participant seated in the same position as the baseline blood draw. Samples were collected in SST clot agent Vacutainer tubes, centrifuged, and stored as described previously. After they had been returned to room temperature (22 °C), insulin levels were analyzed from serum through an enzyme immunoassay kit (Biomeda, Inc.).
Each participant completed a muscle-function test 22-24 hr after the cycling bout. This test consisted of a standard warm-up at ~50% of 1RM, followed by performing the maximal number of repetitions to fatigue at 70% of 1RM on the Cybex leg-extension machine as previously described. The test administrator recorded the number of consecutive repetitions that were completed through the full range of motion (approximately 90°) before fatigue.
A subjective rating of muscle soreness was obtained for each participant at baseline and 22-24 hr after each cycling bout. A 7-point Likert scale was used to assess perceptions of muscle soreness, for comparison with previous investigations of CHO+Pro treatments Romano-Ely et al., 2006) .
Participants consumed 250 ml of treatment beverage at 15-min intervals (1.0 L/hr). One of four treatment beverages was consumed in each experimental ride: a carbohydrate-protein beverage (CHO+Pro; 77.5 g CHO/hr, 19.4 g protein/hr), a carbohydrate beverage matched with CHO+Pro for carbohydrate calories (CHO; 77.5 g CHO/hr), a second carbohydrate beverage matched with CHO+Pro for total calories (CHO+CHO; 96.9 g CHO/hr), and a placebo (PLA; 0 g CHO or protein). All beverages were provided by PacificHealth Laboratories and were orange flavored and colored. The CHO content of the beverages consisted of sucrose and maltodextrin, and the added protein in the CHO+Pro beverage was a whey-protein concentrate. The placebo beverage was sweetened with a noncaloric artificial sweetener and matched, by the manufacturer, for taste and texture. Specific nutrition content of the treatment beverages is provided in Table 2 .
Phases 3-5
Participants returned after a 5-to 10-day washout period and repeated the same protocols as in Phase 2. The only difference was the administration of an alternative beverage. This procedure was repeated in subsequent phases following identical parameters until each participant had completed trials with all four beverages. Treatment beverages were administered using a double-blind protocol. Before exercise trials, a laboratory volunteer who was not involved in data collection prepared the beverages and labeled each container with an A, B, C, or D. Beverage identification was not revealed until completion of the study. Participants performed their respective trials at approximately the same time of day and at the same ambient temperature (20-22 °C). All timing devices were hidden from the participants before the start of exercise, and no feedback on performance was provided to them until the completion of the study.
Participants were instructed to keep dietary records for 24 hr before each cycling trial and received instruction regarding the reporting of standard serving sizes. In addition, participants were instructed to consume nothing but water for 3 hr before each trial. After the first trial, participants were provided with a copy of their dietary intake and instructed to maintain a consistent diet before subsequent exercise trials. Dietary records were visually inspected before each trial to ensure no obvious variations in dietary intake between trials for each participant. Statistical analyses were not performed on these data, so it is possible that systematic variations in nutritional intake influenced results, particularly in regard to variations in time to exhaustion. In a separate subset of cyclists, however, we recently observed no between-trials differences in carbohydrate, fat, protein, or total caloric intake when using these same dietary instructions (manuscript in preparation). In addition, between-participants variations in dietary intake before exercise trials did not influence whether participants were "responders" to CHO+Pro with respect to time to exhaustion or markers of postexercise recovery. In addition to dietary controls, participants were instructed to keep a record of physical activity for 48 hr before each cycling trial. This was replicated as closely as possible before the three subsequent cycling trials. Consistency in dietary intake and physical activity was important to control for initial muscle glycogen levels, which have been shown to be related to time to exhaustion (Bergstrom, Hermansen, Hultman, & Saltin, 1967; Devlin & Williams, 1991) .
Statistical Analyses
Performance data were compared between beverage trials with a repeated-measures analysis of variance (ANOVA), using Statistical Package for the Social Sciences (SPSS), Version 12.0, for Windows. Treatment differences in metabolic variables obtained during the rides were analyzed using two-way (Treatment × Time) repeated-measures ANOVAs. When appropriate, Tukey's post hoc analyses were used to examine differences between individual treatments. Statistical analyses of VO 2 , RER, RPE, and HR were performed using data from exercise onset and late exercise (the final time point that was common to all trials for each participant). Analyses for glucose and lactate were performed using data from exercise onset and end-exercise. Treatment differences in insulin were compared from samples obtained immediately preexercise and end-exercise.
Plasma CK and Mb were compared between preexercise and postexercise using two-way (Treatment × Time) repeated-measures ANOVAs. Treatment differences in postexercise muscle function were analyzed using repeated-measures ANOVA. Treatment differences between individual beverages were examined using Tukey's post hoc analyses. Postexercise muscle-soreness scores were compared between trials using a nonparametric Friedman test for related samples. All statistical analyses were considered significant at an alpha level of p < .05. 
Results
Performance
Eleven participants completed all four trials to volitional exhaustion. One participant failed to ride to exhaustion because of stomach cramps in two trials, so his performance data were excluded from analyses. Mean performance time to exhaustion between beverages is depicted in Figure 2 . Participants rode significantly longer (p < .05) in the CHO+Pro and CHO+CHO treatments than in PLA (18% and 13%, respectively). The difference in time to exhaustion between the CHO trial and PLA trial (9.7%) was not significant. Similarly, differences in time to exhaustion between the CHO+Pro versus CHO and CHO+CHO treatments (7.4% and 4.0%, respectively) were not statistically significant.
Metabolic Measures During Exercise
Metabolic measurements obtained during exercise are displayed in Table 3 . Two participants did not reach 60 min of exercise duration in at least one trial, so data are depicted only for the time points that were common to all participants, as described in the table legend. Blood glucose levels did not change during exercise in the PLA trial but increased significantly (p < .05) in all other trials. Blood lactate levels decreased from the onset of exercise to end-exercise in all trials and were not significantly different between treatments. RER decreased over the course of the trials, and the decrease was not significantly different between treatments.
VO 2 increased slightly during all trials. HR followed a similar trend, although the increase was only significant in the CHO+CHO trial. RPE also rose significantly during all trials, with the rise in the CHO+Pro trial significantly lower than that in the CHO trial. Serum insulin levels were maintained in all trials except PLA, resulting in significantly lower end-exercise insulin in the PLA trial than in all other treatments.
Muscle-Disruption Indices
There were no differences in pretest values for CK or Mb between treatments. Postexercise CK concentrations increased significantly (p < .05) from preexercise values for PLA (91%), CHO (119%), and CHO+CHO (116%) but not for CHO+Pro (-8%). As a result, postexercise CK values were significantly lower in the CHO+Pro trial than the PLA, CHO, and CHO+CHO trials (Figure 3) . Similarly, Mb concentrations increased significantly after exercise in the PLA (392%), CHO (163%), and CHO+CHO (174%) trials but not after the CHO+Pro trial (37%). Postexercise Mb concentrations were significantly lower in the CHO+Pro trial than in the PLA, CHO, and CHO+CHO trials. In addition, postexercise Mb concentrations were significantly higher in the PLA trial than either CHO trial (Figure 4) .
Significantly more leg-extension repetitions were completed after the CHO+Pro trial than after the PLA, CHO, and CHO+CHO trials (see Figure 5 ). In addition, significantly more repetitions were completed in the CHO trial than in the PLA trial. Postexercise muscle soreness was not significantly different between any treatments (see Figure 6 ).
Discussion
Time to Exhaustion
CHO+Pro supplements consumed during prolonged exercise have been reported to improve endurance time to exhaustion when compared with CHO beverages matched for carbohydrate content Saunders et al., 2004 Saunders et al., , 2007 but not total caloric content (Romano-Ely et al., 2006) . Each of those studies, however, compared beverages containing less than peak exogenous oxidation rates of carbohydrate, making it difficult to determine whether improvements in endurance were related to variations in total energy intake or specifically resulted from a protein-mediated effect. Ingesting single carbohydrate forms during exercise might allow maximal exogenous oxidation rates of up to 60-72 g CHO/hr (Jeukendrup & Jentjens, 2000) . Mixtures of multiple carbohydrate sources elicit higher levels of oxidation during exercise, potentially through different absorptive pathways for individual carbohydrates (Jentjens, Moseley, et al., 2004; Jentjens, Venables, & Jeukendrup, 2004) . Because the carbohydrate content of all carbohydrate beverages in the current study equaled or exceeded peak exogenous carbohydrate-oxidation levels, we hypothesized that time to fatigue would vary between treatments in the following manner: PLA < CHO = CHO+CHO < CHO+Pro. Although the rank order of performance times across the four treatments was consistent with our hypothesis, statistical analyses were inconclusive in demonstrating significant differences between some treatments. CHO+Pro and CHO+CHO beverages significantly outperformed PLA, but CHO did not significantly differ from PLA. Similarly, time to exhaustion between CHO, CHO+CHO, and CHO+Pro treatments did not differ from each other. Time to exhaustion was used as a measure of endurance in the current study to enable direct comparison with previous studies on this topic (Romano-Ely et al., 2006; Saunders et al., 2004 Saunders et al., , 2007 . Time-to-exhaustion protocols, however, have been shown to elicit greater error variance between repeated trials than other endurance protocols (Jeukendrup, Saris, Brouns, & Kester, 1996) . Prior studies have been successful in detecting performance differences between CHO+Pro and CHO treatments using similar time-to-exhaustion protocols (Saunders et al., 2004 . Although others have used time-to-exhaustion protocols, it is likely that error variance was compounded by the four-trial protocol in the current study, which lengthened the testing period (≥4 weeks) and allowed potential time for alterations in participant performance. As a result, there might have been inadequate sensitivity to detect potentially important differences (4.0-7.4%) between CHO+Pro and carbohydrate (CHO and CHO+CHO) beverages. Time trials might elicit lower variance between repeated trials (Jeukendrup et al.) and should be used in future investigations. In the only published time-trial comparison of CHO and CHO+Pro beverages to date, van Essen and Gibala (2006) reported no differences in endurance time-trial performance between CHO and CHO+Pro treatments. As discussed by Saunders (2007) , however, that study might also have been limited by inadequate statistical power, which was estimated to be β = 0.32 to detect a theoretical 2-min difference between treatments. To more conclusively determine the effects of CHO+Pro on endurance performance, it is recommended that future studies examine time-trial performance differences in late exercise and use large enough sample sizes to detect "practically significant" differences in performance between beverages.
The current study supports previous investigations showing that CHO+Pro beverages improve endurance performance versus placebo beverages when using time-to-exhaustion ) or time-trial (van Essen & Gibala, 2006 protocols. No statistically significant differences were observed between CHO+Pro (77.5 g CHO/hr; 19.4 g protein/hr), CHO (77.5 g CHO/hr), or CHO+CHO (96.9 g CHO/hr) beverages in this study. Others Saunders et al., 2004 Saunders et al., , 2007 have reported that CHO+Pro ingestion resulted in 13-36% improvements in time to exhaustion over beverages with lower CHO content (37-47 g CHO/hr), suggesting that performance improvements with CHO+Pro are greatest when carbohydrate intake is below maximal exogenous ingestion rates. The observation that time to exhaustion was 4.0-7.4% higher (NS) in the CHO+Pro trial in this study, however, suggests that further research is required to confirm whether performance benefits of CHO+Pro are present at reduced levels when carbohydrate intake is maximized.
As discussed by Saunders (2007) , calorically independent benefits of CHO+Pro might be the result of glycogen sparing, maintenance of tricarboxylic acid cycle intermediates, attenuation of central fatigue, altered fluid or substrate uptake from the intestines, or augmented insulin stimulation with CHO+Pro ingestion. These mechanisms are currently speculative, however; there is little evidence to directly show that CHO+Pro ingestion induces more favorable responses in any of these potential mechanisms versus CHO only. The current study was not designed to specifically examine calorically independent mechanisms. Nonetheless, we observed that end-exercise insulin levels in the CHO+Pro trial were significantly higher than in the placebo trial but not significantly different than either carbohydrate trial. These findings are similar to those reported by Ivy et al. (2003) and suggest that improvements in endurance performance with CHO+Pro ingestion are not caused by augmented insulin levels during exercise.
Indices of Muscle Disruption
Carbohydrate-protein beverages reportedly reduce indices of postexercise muscle disruption when compared with CHO beverages matched for carbohydrate content (Saunders et al., 2004) or total calories (Romano-Ely et al., 2006) . Previous studies reported attenuated levels of plasma CK (Romano-Ely et al.; Saunders et al., 2004) , lactate dehydrogenase, and subjective ratings of muscle soreness (Romano-Ely et al.) 12-24 hr after exhaustive cycling with CHO+Pro ingestion. These findings suggest that CHO+Pro ingestion might attenuate postexercise muscle damage, but none of these studies used biopsy or MRI techniques to assess direct measurements of myofibrillar disruption. In addition, it is unclear whether the treatment differences in plasma CK reported in the cited studies represent a functionally relevant effect. In the current study, lower postexercise CK and Mb concentrations were observed after the CHO+Pro treatment than after all other treatments. In addition, CK and Mb were significantly increased after PLA, CHO, and CHO+CHO trials but not after CHO+Pro. Although further studies are required to determine whether direct measurements of muscle damage are affected by CHO+Pro ingestion, the observed attenuations in sarcolemmal disruption with CHO+Pro in this study had functional relevance, because the number of repetitions performed at 70% 1RM 24 hr after exercise was significantly higher with the CHO+Pro treatment than all other treatments.
The improved muscle function observed after CHO+Pro ingestion might have practical implications for performance in subsequent exercise. Saunders et al. (2004) observed significant attenuations in postexercise plasma CK levels after CHO+Pro administration, which were accompanied by improvements in subsequent endurance-exercise performance. Romano-Ely et al. (2006) , however, observed no differences in subsequent performance between CHO and CHO+Pro beverages, despite postexercise reductions in plasma CK with CHO+Pro. Differences in these findings might result from relative differences in muscle disruption in these studies, because the postexercise CK response elicited when CHO+Pro was not consumed was much greater in the participants of Saunders et al. (~1,300 U/L) than those of Romano-Ely et al. (~580 U/L). This hypothesis is supported by subsequent analyses of the data from Saunders et al. (2004) , in which it was reported that participants with the largest attenuations in plasma CK with CHO+Pro administration also had the largest improvements in subsequent performance (Combest, Saunders, Kane, & Todd, 2005) . Similarly, Luden et al. (2007) reported that runners who observed the largest attenuations in plasma CK levels with postexercise CHO+Pro ingestion had the greatest tendency for enhanced running performance in a subsequent bout of exercise. This suggests that CHO+Pro consumption might be most beneficial to athletes who engage in very hard, long, or frequent exercise. Further investigation is required, however, to determine specific circumstances under which CHO+Pro ingestion produces functionally important changes in recovery and subsequent performance, because results of previous studies on this topic have been mixed (Betts et al., 2005; Luden et al.; Millard-Stafford et al., 2005; Niles et al., 2001; Romano-Ely et al.; Saunders et al., 2004; Williams, Raven, Fogt, & Ivy, 2003) .
Data from the current study support previous studies, suggesting that carbohydrate ingestion alone might have some positive effects on postexercise muscle recovery (Greer, Woodard, White, Arguello, & Haymes, 2007; van Hamont et al., 2005) . For example, serum Mb and muscle function were significantly improved after both carbohydrate trials (CHO and CHO+CHO) compared with PLA. The effects of carbohydrate were not improved further, however, with increased levels of carbohydrate intake; there were no differences between CHO and CHO+CHO treatments for any postexercise measurements. This finding suggests that protein per se is responsible for the reported effects of CHO+Pro, because postexercise responses in the CHO+Pro trial were improved to a greater extent than carbohydrate beverages matched for carbohydrate content and total calories. In addition, the current study provides evidence supporting the efficacy of CHO+Pro consumed only during exercise. Previous studies reporting attenuated levels of plasma CK and muscle soreness with CHO+Pro ingestion provided beverages both during and immediately after exercise (Romano-Ely et al., 2006; Saunders et al., 2004) . The current study demonstrates that these effects might also be observed when CHO+Pro is only consumed during exercise.
In summary, this experiment was designed to compare the effects of placebo, carbohydrate, and carbohydrate-protein beverages on endurance and markers of muscle disruption. Carbohydrate beverages were matched in carbohydrate or total calories to the CHO+Pro beverage, at levels that were intended to equal or exceed exogenous carbohydrate-oxidation levels. The CHO+Pro beverage produced the longest time to exhaustion, although this was not significantly longer than with either carbohydrate beverage. In addition, the CHO+Pro beverage significantly attenuated postexercise changes in CK, Mb, and muscle dysfunction compared with the PLA and both carbohydrate beverages. These findings suggest that at least some of the reported improvements in endurance performance with CHO+Pro beverages might be related to caloric differences between treatments. Postexercise improvements in markers of muscle disruption with CHO+Pro ingestion appear to be independent of carbohydrate and caloric content of the beverages and were elicited with beverages consumed only during exercise.
